Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Shares of Agios Pharmaceuticals, Inc. (AGIO) are currently gaining over 32% after the company announced plans to sell its cancer treatment business to Servier for up to $2 billion.


RTTNews | Dec 21, 2020 10:28AM EST

10:27 Monday, December 21, 2020 (RTTNews.com) - Shares of Agios Pharmaceuticals, Inc. (AGIO) are currently gaining over 32% after the company announced plans to sell its cancer treatment business to Servier for up to $2 billion.

AGIO is currently trading at $43.96, up $10.75 or 32.36%, on the Nasdaq.

Agios Pharmaceuticals, a company focused to treat cancer and rare genetic diseases, announced it has agreed to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent pharmaceutical company.

Agios will receive a cash consideration of up to $2.0 billion, including $1.8 billion in upfront cash and $200 million in a potential future milestone payment for vorasidenib, as well as 5% royalties on U.S. net sales of ivosidenib tablets.

Agios said that it will move forward with a focus on accelerating and expanding its genetically defined disease portfolio, including the mitapivat clinical programs and a robust pipeline of therapeutic candidates.

Read the original article on RTTNews ( https://www.rttnews.com/3155420/stock-alert-agios-pharma-jumps-30-on-deal-to-sell-cancer-biz-to-servier.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC